Long-term efficacy and safety data of lomitapide in HoFH
Anti-inflammatory therapies for CVD risk prevention
Ulrich Laufs, MD, PhD
Novel PCSK9 inhibitor lowers LDL-c in another large phase 3 study
Evan Stein, MD, PhD
LDL-c lowering with PCSK9 inhibitor in ASCVD patients without acute ischemic event
Pasquale Perrone-Filardi, MD, PhD
Rationale for dietary fat recommendations in ASCVD prevention
Jacob J. Christensen, PhD
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.
